Nyxoah S.A. (NYXH) vs Pyxis Oncology, Inc. (PYXS)
A side-by-side comparison of Nyxoah S.A. and Pyxis Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NYXH
Nyxoah S.A.
$1.44HealthcareDelayed quote: Oct 6, 2026, 12:26 PM EDT
PYXS
Pyxis Oncology, Inc.
$2.11HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
Total return — NYXH vs PYXS
growth of $100 · dividends reinvested · last 5yNYXH -94.8% (-44.6%/yr)PYXS -83.0% (-29.9%/yr)PYXS compounded faster over this window
NYXH PYXS
NYXH vs PYXS: by the numbers
- •NYXH is the larger company ($144M vs $134M market cap).
- •Both run net losses; NYXH's is the smaller (-435.70% vs -803.83% net margin).
Metrics side by side
Valuation
| Metric | NYXH | PYXS |
|---|---|---|
| P/S ratio | 5.48 | 12.12 |
| P/B ratio | 1.51 | 11.70 |
Profitability
| Metric | NYXH | PYXS |
|---|---|---|
| Gross margin | 63.13% | 82.77% |
| Operating margin | -827.76% | -609.18% |
| Net margin | -435.70% | -803.83% |
| ROE | -120.33% | -775.59% |
| ROIC | -61.13% | -314.66% |
Growth (annualized)
| Metric | NYXH | PYXS |
|---|---|---|
| Revenue CAGR (5Y) | 120.68% | N/A |
| Total return CAGR (5Y) | -45.84% | N/A |
Go deeper
Dig into the metrics
Nyxoah ROEPyxis Oncology ROENyxoah operating marginPyxis Oncology operating marginNyxoah revenue growthPyxis Oncology revenue growthNyxoah free cash flowPyxis Oncology free cash flow
Nyxoah & Pyxis Oncology appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.